Cover Image
市場調查報告書

金磚四國的成藥市場:∼2025年

The BRIC OTC Market to 2025

出版商 GMR Data Ltd 商品編碼 486813
出版日期 內容資訊 英文 126 Pages
訂單完成後即時交付
價格
Back to Top
金磚四國的成藥市場:∼2025年 The BRIC OTC Market to 2025
出版日期: 2017年04月04日 內容資訊: 英文 126 Pages
簡介

本報告提供巴西,俄羅斯,印度,調查中國的成藥的市場,世界市場趨勢,市場促進因素、阻礙要素分析,金磚四國各國的市場背景,市場規模的變化與預測,各醫藥品種類的明細,法律制度,市場推動因素分析,主要的國內企業,金磚四國打入市場的主要企業簡介,SWOT分析,專家的見解等彙整資料。

第1章 摘要整理

第2章 簡介

第3章 金磚四國的成藥市場:市場預測

  • 全球市場的預測
  • 全球市場的預測:各OTC種類
  • 市場概要
    • 經濟指標
  • 金磚四國的成藥醫藥品:變化與預測
  • 巴西
    • 國家背景
    • 市場變化與預測
    • 市場成果、預測:各種類
      • 護膚
      • CC&A
      • 止痛藥
      • 維生素和礦物質、補充品(VM&S)
    • 成長推動因素
    • OTC企業
      • Ache Laboratorios Farmaceuticos
      • Hypermarcas
      • EMS
      • Apsen Farmaceutica
  • 俄羅斯
    • 國家背景
    • 市場變化與預測
    • 市場成果、預測:各種類
      • CC&A
      • 胃腸藥
      • 止痛藥
    • 主要企業
      • Pharmstandard JSC
    • 法律制度
    • 成長推動因素
  • 印度
    • 國家背景
    • 市場變化與預測
    • 市場成果、預測:各種類
      • VM&S
      • 咳嗽、感冒
      • 止痛藥
    • 法律制度
    • 成長推動因素
  • 中國
    • 國家背景
    • 市場變化與預測
    • 市場成果、預測:各種類
      • 咳嗽、感冒、過敏
      • VM&S
      • 止痛藥
    • 法律制度
    • 成長推動因素

第4章 主要企業

  • Bayer
  • Boehringer Ingelheim
  • GlaxoSmithKline (GSK)
  • Johnson & Johnson
  • Merck
  • Novartis
  • Perrigo
  • Pfizer
  • Procter & Gamble
  • Reckitt-Benckiser
  • Sanofi

第5章 SWOT分析

第6章 專家的見解

  • Novartis
  • Ranbaxy
  • Sanofi
目錄
Product Code: BRICOTC

GMR Data's new Pharmaceutical report is released today detailing The Brazil, Russia, India and China Over-the-Counter Pharmaceuticals Market to 2025. The report draws on knowledge of experts in the field, in depth company research and up to date tracking of trends in the OTC sector.

By exploring and comparing these key 4 markets GMR Data aim to give the reader the best indication of how these markets will progress to 2025; which OTC areas will offer the most growth and what location specific issues any entrant to the respective OTC markets can face.

In this brand new 126-page report you will receive 70 tables and 35 figures - all unavailable elsewhere. By ordering and reading our brand new report today you stay better informed and ready to act.

The report provides clear detailed insight into the BRIC OTC. Discover the key drivers and challenges affecting the market.

Drivers include

  • Growing awareness of OTC products amongst consumers
  • Increasing purchasing power parity of the consumers
  • Increasing NCD population will drive OTC demand in BRIC nations

Restraints include

  • Stringent regulations
  • Infrastructural Challenges - distribution networks

The income disparity in emerging BRIC countries is comparatively high when compared to developed nations. This is the fundamental challenge faced by multinationals operating in these markets. Whereas growing populations and increasing consumer awareness for self-medication are important factors driving the demand.

GMR Data's The Brazil, Russia, India and China Over-the-Counter Pharmaceuticals Market to 2025 also benefits from 3 exclusive interviews with representatives from;

  • Novartis
  • Ranbaxy
  • Sanofi

These leading, in the field, experts offer exclusive insight into the BRIC OTC sector; how they see the market currently, which geographical areas will witness growth and which sub sectors / OTC drugs face perhaps face an uncertain growth trajectory.

With the growing economies of the BRIC countries, the purchasing power of the general population is increasing, which in turn increases the market size for OTC products.

Table of Contents

1 - Executive Summary

  • 1.1 Executive Summary
  • 1.2 Research and Analysis Methods
  • 1.3 Drivers & Restraints of the BRIC OTC Market to 2025
    • 1.3.1 Drivers
      • 1.3.1.1 Growing awareness of OTC products amongst consumers
      • 1.3.1.2 Increasing purchasing power parity of the consumers
      • 1.3.1.3 Increasing elderly, smoking and obese population to drive OTC demand in BRIC
      • 1.3.1.4 Favourable government regulations and promotion of OTC products in emerging markets
    • 1.3.2 Restraints
      • 1.3.2.1 Stringent regulatory actions
      • 1.3.2.2 Infrastructural Challenges

2 - Introduction to the BRIC OTC Market to 2025

  • 2.1 OTC Pharmaceuticals
    • 2.1.1 Classification of OTC Pharmaceuticals in BRIC Nations
  • 2.2 Market Segmentation of OTC Pharmaceuticals

3 - The BRIC OTC Market to 2025

  • 3.1 Global OTC Pharmaceutical Market to 2025
  • 3.2 Breakdown by OTC Segment, Globally, 2014 - 2025
  • 3.3 BRIC OTC Pharmaceuticals Market Overview
    • 3.3.1 Economic Indicators, BRIC Countries, 2013
  • 3.4 BRIC OTC Pharmaceuticals Market, 2013-2025
    • 3.4 The Brazil OTC Pharmaceuticals Market Overview to 2025
    • 3.4.1 Overview of Brazil
    • 3.4.2 Brazil OTC Pharmaceuticals Market, 2014-2025
    • 3.4.3 Breakdown by Segment, Brazil, 2014 and 2025
      • 3.4.3.1 Skin Care
      • 3.4.3.2 CC&A
      • 3.4.3.3 Analgesics
      • 3.4.3.4 Vitamins, Minerals & Supplements (VM&S)
  • 3.5 Drivers for OTC Pharmaceuticals Growth, Brazil
    • 3.5.1 Expansion of distribution channels
    • 3.5.2 Favourable government regulations for OTC
    • 3.5.3 Affordability of OTC products
    • 3.5.4 Increasing middle class
    • 3.5.5 Increase in non-communicable disease
    • 3.5.6 OTC Companies in Brazil
      • 3.5.6.1 Aché Laboratórios Farmacêuticos
      • 3.5.6.2 Hypermarcas
      • 3.5.6.4 EMS
      • 3.5.6.5 Apsen Farmacêutica
  • 3.6 The Russia OTC Pharmaceuticals Market Overview, to 2025
    • 3.6.1 Overview of Russia
    • 3.6.2 Russia OTC Pharmaceuticals Market, 2013-2025
    • 3.6.3 Breakdown By Segment, Russia
      • 3.6.3.1 CC&A
      • 3.6.3.2 Digestives
      • 3.6.3.3 Analgesics
    • 3.6.4 Key Domestic Companies in the Russian OTC Market
      • 3.6.4.1 Pharmstandard JSC
    • 3.6.5 Regulatory Environment, Russia
    • 3.6.6 Drivers for OTC Pharmaceuticals Growth, Russia
      • 3.6.6.1 Growing popularity of direct and online sales channels
      • 3.6.6.2 Growing disposable income
      • 3.6.6.3 Growing incidence of non-communicable diseases
  • 3.7 The India OTC Market Overview, to 2025
    • 3.7.1 Overview of India
    • 3.7.2 India OTC Pharmaceuticals Market to 2025
    • 3.7.3 Breakdown by Segment, India, 2013 and 2025
      • 3.7.3.1 VM&S
      • 3.7.3.2 Cough and Cold
      • 3.7.3.3 Analgesics
    • 3.7.4 Regulatory Environment, India
    • 3.7.5 Drivers for OTC Pharmaceuticals Growth, India
      • 3.7.5.1 Consumer behaviour
      • 3.7.5.2 Wide distribution
      • 3.7.5.3 Liberal regulatory procedures
      • 3.7.5.4 Availability of OTC Products
      • 3.7.5.5 Margins on OTC Products
  • 3.8 The China OTC Market Overview to 2025
    • 3.8.1 Overview of China
    • 3.8.2 China OTC Pharmaceuticals Market to 2025
      • 3.8.2.1 Cough, Cold & Allergy
      • 3.8.2.2 VM&S
      • 3.8.2.3 Analgesics
    • 3.8.3 Breakdown by Segment, China, 2013 and 2025
    • 3.8.4 Regulatory Environment, China
    • 3.8.5 Drivers for OTC Pharmaceuticals Growth, China
      • 3.8.5.1 Economic performance
      • 3.8.5.2 Increase in smoking / obese population
      • 3.8.5.3 Increase in the elderly population
      • 3.8.5.4 Growth in consumer awareness and self-medication

4 - Leading companies in the BRIC OTC Market

  • 4.1 Leading companies in the BRIC OTC Market
  • 4.2 Bayer
    • 4.2.1 Bayer's Company Overview
    • 4.2.2 Bayer's Key OTC Products
    • 4.2.3 Bayer's Financial Performance
    • 4.2.4 BRIC Developments from Bayer
  • 4.3 Boehringer Ingelheim
    • 4.3.1 Boehringer Ingelheim's Company Overview
    • 4.3.2 Boehringer Ingelheim's Key OTC Products
    • 4.3.3 Boehringer Ingelheim's Financial Performance
    • 4.3.4 BRIC Developments from Boehringer Ingelheim
  • 4.4 GlaxoSmithKline (GSK)
    • 4.4.1 GSK's Company Overview
    • 4.4.2 GSK Key OTC Products
    • 4.4.3 GSK's Financial Performance
    • 4.4.4 BRIC Developments from GSK
  • 4.5 Johnson & Johnson
    • 4.5.1 Johnson & Johnson Company Overview
    • 4.5.2 Johnson & Johnson Key OTC Products
    • 4.5.3 Johnson & Johnson Financial Performance
    • 4.5.4 BRIC Developments from Johnson & Johnson
  • 4.6 Merck
    • 4.6.1 Merck's Company Overview
    • 4.6.2 Merck's Financial Performance
    • 4.6.3 BRIC Developments from Merck
  • 4.7 Novartis
    • 4.7.1 Novartis's Company Overview
    • 4.7.2 Novartis Key OTC Products
    • 4.7.3 Novartis's Financial Performance
    • 4.7.4 Recent BRIC Developments from Novartis
  • 4.8 Perrigo
    • 4.8.1 Perrigo's Company Overview
    • 4.8.2 Perrigo Key OTC Products
    • 4.8.3 Perrigo's Financial Performance
    • 4.8.4 Recent BRIC Developments from Perrigo
  • 4.9 Pfizer
    • 4.9.1 Pfizer's Company Overview
    • 4.9.2 Pfizer Key OTC Products
    • 4.9.3 Pfizer's Financial Performance
    • 4.9.4 Recent BRIC Developments from Pfizer
  • 4.10 Procter & Gamble
    • 4.10.1 Proctor & Gamble Company Overview
    • 4.10.2 Proctor & Gamble Key OTC Products
    • 4.10.3 Proctor & Gamble Financial Performance
    • 4.10.4 Recent BRIC Developments from Procter & Gamble
  • 4.11 Reckitt-Benckiser
    • 4.11.1 Reckitt-Benckiser Company Overview
    • 4.11.2 Reckitt-Benckiser Key OTC Products
    • 4.11.3 Reckitt Benckiser's Financial Performance
    • 4.11.4 Recent Developments from Reckitt Benckiser
  • 4.12 Sanofi
    • 4.12.1 Sanofi's Company Overview and Key products
    • 4.12.2 Sanofi's Key OTC Products
    • 4.12.3 Sanofi's Financial Performance
    • 4.12.4 Recent Developments from Sanofi

5- SWOT Analysis of the BRIC OTC Market to 2025

  • 5.1 SWOT Analysis
    • 5.1.1 Strengths:
      • 5.1.1.1 Regulators are encouraging OTC approvals
      • 5.1.1.2 Strong potential of OTC portfolio
      • 5.1.1.3 Economic Advantages
      • 5.1.1.4 Growing consumer awareness and self-medication
      • 5.1.1.5 Increased purchasing power in emerging markets
    • 5.1.2 Weaknesses
      • 5.1.2.1 High focus on prescription and generic drugs
      • 5.1.2.2 OTC products are vulnerable to price fluctuations
      • 5.1.2.3 Inadequate Investment in infrastructure
      • 5.1.2.4 Lack of proper health insurance system in BRIC
      • 5.1.2.5 Income disparity
      • 5.1.2.6 Distribution network
    • 5.1.3 Opportunities
      • 5.1.3.1 Increase in the Number of Self-administering Patients
      • 5.1.3.2 Opportunities in social media and online marketing
      • 5.1.3.3 Strong growth in the emerging / BRIC markets
      • 5.1.3.4 Demographic changes
      • 5.1.3.5 Growing health problems such as smoking and obese population
      • 5.1.3.6 Improving the healthcare system
    • 5.1.4 Threats:
      • 5.1.4.1 Resistance to OTC switching for some groups (CNS, CVS)
      • 5.1.4.2 Competition from private label brands will reduce profits
      • 5.1.4.3 Regulatory concerns

6- Expert Opinion

  • 6.1 Novartis
  • 6.2 Ranbaxy
  • 6.3 Sanofi

Companies

  • Abbott
  • Aché Laboratórios Farmacêuticos
  • Agência Nacional de Vigilância Sanitária
  • Apsen Farmacêutica
  • Bayer
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • China State Food & Drug Administration (SFDA)
  • CIA
  • Conselho Nacional de Autorregulamentacao Publicitaria (CONAR)
  • CR Sanjiu Medical
  • Dabur
  • Elder Pharma
  • EMS
  • GlaxoSmithKline (GSK)
  • GMR Data
  • Grupo Menarini
  • Hypermarcas
  • IMF
  • Johnson & Johnson
  • Merck
  • Novartis
  • Nycomed
  • OECD
  • Perrigo
  • Pfizer
  • Pharmastandard
  • Pharmstandard JSC
  • Procter & Gamble
  • Ranbaxy
  • Reckitt-Benckiser
  • Sanofi
  • Sanofi-Aventis
  • Sanofi-Aventis Farmacêutica
  • STADA
  • Sun Pharmaceuticals
  • Takeda
  • TEVA
  • The Federal Service on Surveillance in Healthcare and Social Development (Roszdravnadzor)
  • União Química Farmacêutiva Nacional
  • World Bank
Back to Top